Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.52 USD | +0.74% | -3.04% | +18.13% |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
May. 31 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.13% | 2.02B | |
-4.52% | 12.39B | |
-0.60% | 8.43B | |
+6.71% | 5.77B | |
+32.42% | 5.76B | |
-10.21% | 4.1B | |
+10.62% | 2.66B | |
-61.39% | 2.66B | |
-8.27% | 2.39B | |
-9.18% | 1.77B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Morningstar Downgrades Myriad Genetics to Sell From Hold, $18.50 Price Target